Biodesix Inc (BDSX) Stock Price, Quote & News

Company Profile

Biodesix, Inc. operates as a diagnostic solutions company. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests markets as Nodify Lung Nodule Risk Assessment testing to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR, GeneStrat NGS, and VeriStrat tests markets as part of IQLung testing strategy,...

Industry: Diagnostics & Research

Sector: Healthcare

Phone: 303 417 0500

Fax: 866 432 3338

Website: www.biodesix.com

Address:

919 West Dillon Road, Louisville, United States

supplySHOCK Jun. 4 at 10:09 AM

$NSYS $AKAN $BDSX $SMX figure

0 · Reply

supplySHOCK Jun. 3 at 9:08 PM

$BDSX $SNSE $AIOS $AKTX name

0 · Reply

G101SPM May. 22 at 12:59 PM

#DILUTION Ameris Bancorp ($ABCB) files mixed securities shelf offering Babcock & Wilcox Enterprises ($BW) files for 11,657,221 share common stock offering by selling stockholders Biodesix ($BDSX) files for 375,000 share common stock offering by selling stockholders Galaxy Digital ($GLXY) files for resale of up to 265,061,636 shares of Class A common stock Ondas Inc. ($ONDS) filed prospectus supplement on May 22 to its effective registration statement on Form S-3ASR covering the resale from time to time by certain stockholders of 2,738,224 shares

0 · Reply

focafoca99 May. 20 at 8:34 PM

$BDSX elected two new Class III directors at its 2026 annual meeting.

0 · Reply

AdrianCartier May. 5 at 6:51 PM

$BDSX finally some green

0 · Reply

Johndoe456 May. 5 at 2:57 PM

$BDSX

0 · Reply

topstockalerts May. 5 at 11:01 AM

Pre Market Top Gainers PT2 $VEEE $EVER $BDSX $PINS $GURE

0 · Reply

captain5500 May. 5 at 8:14 AM

$BDSX delivered on earnings 💥💥

0 · Reply

topstockalerts May. 5 at 1:58 AM

After Hours Top Gainers PT2 $GSUN $CWD $BDSX $EVER $PINS

0 · Reply

StocktwitsEarnings May. 4 at 8:09 PM

$BDSX Q1 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.81 up 49.38% YoY • Reported revenue of $25.55M up 42.30% YoY • For full year 2026, Biodesix expects total revenue of $108.11B, with the midpoint reflecting approximately 25% growth over 2025. Biodesix also expects continued progress toward achieving and maintaining Adjusted EBITDA profitability.

0 · Reply

Biodesix Transcript: 46th Annual William Blair Growth Stock Conference

2026-05-21T20:46:14.000Z - 14 days ago

Biodesix files to sell 375,000 shares of common stock for holders

May 21, 2026, 8:00 AM EDT - 14 days ago

Biodesix Registration statement: Registration filing

May 21, 2026, 6:00 AM EDT - 14 days ago

Biodesix to Participate in Upcoming Investor Conferences

May 11, 2026, 9:17 AM EDT - 24 days ago

Biodesix Announces ATS 2026 Presentations Providing Real-World Clinical Evidence and Healthcare System Economic Value for Nodify Lung® Testing Strategy

2026-05-05T10:50:00.000Z - 4 weeks ago

Biodesix price target raised to $22 from $20 at Canaccord

2026-05-04T20:30:28.000Z - 4 weeks ago

Biodesix reports Q1 EPS (81c) vs. ($1.52) last year

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Biodesix Earnings Call Transcript: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Biodesix Earnings release: Q1 2026

May 4, 2026, 4:30 PM EDT - 4 weeks ago

Biodesix Quarterly report: Q1 2026

2026-05-04T20:28:11.000Z - 4 weeks ago

Biodesix raises FY26 revenue view to $108M-$114M from $106M-$112M

May 4, 2026, 4:01 PM EDT - 4 weeks ago

Biodesix Announces First Quarter 2026 Results and Highlights

May 4, 2026, 7:00 AM EDT - 4 weeks ago

Biodesix Slides: Corporate presentation

Apr 20, 2026, 6:00 AM EDT - 6 weeks ago

Biodesix to Report First Quarter 2026 Financial Results on May 4, 2026

Apr 9, 2026, 1:19 PM EDT - 2 months ago

Biodesix Recognized as a Top Workplace for Third Consecutive Year

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Biodesix Proxy statement: Proxy filing

Apr 9, 2026, 8:00 AM EDT - 2 months ago

Biodesix Proxy statement: Proxy filing

Apr 6, 2026, 11:43 AM EDT - 2 months ago

Biodesix Announces AACR 2026 Posters and Presentations, Highlighting Novel Diagnostic Test Discovery & Pipeline Development

Mar 20, 2026, 8:06 AM EDT - 2 months ago

Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

Mar 11, 2026, 12:00 PM EDT - 3 months ago

Biodesix Transcript: Barclays 28th Annual Global Healthcare Conference

Mar 3, 2026, 2:30 PM EST - 3 months ago

Biodesix Transcript: TD Cowen 46th Annual Health Care Conference

2026-02-27T10:00:18.000Z - 3 months ago

Biodesix upgraded to Outperform from Market Perform at William Blair

Feb 26, 2026, 4:30 PM EST - 3 months ago

Biodesix Earnings Call Transcript: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Biodesix Annual report: Q4 2025

Feb 26, 2026, 4:30 PM EST - 3 months ago

Biodesix Earnings release: Q4 2025

2026-02-26T21:29:27.000Z - 3 months ago

Biodesix sees FY26 revenue $106M-$112M, consensus $105.9M

2026-02-26T21:13:01.000Z - 3 months ago

Biodesix reports Q4 EPS (49c) vs. ($1.13) last year

Feb 26, 2026, 4:01 PM EST - 3 months ago

Biodesix Announces Fourth Quarter and Fiscal Year 2025 Results and Highlights

Feb 12, 2026, 6:00 AM EST - 4 months ago

Biodesix to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026

2026-01-12T16:55:18.000Z - 5 months ago

Biodesix trading resumes

2026-01-12T16:50:32.000Z - 5 months ago

Biodesix trading halted, volatility trading pause

2026-01-12T11:05:50.000Z - 5 months ago

Biodesix sees Q4 revenue $28.8M, consensus $25.02M

Jan 12, 2026, 6:00 AM EST - 5 months ago

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2025 Results (Unaudited)

Dec 3, 2025, 8:22 AM EST - 6 months ago

Biodesix to Present New Data at Two Major Upcoming Scientific Meetings

Nov 3, 2025, 4:30 PM EST - 7 months ago

Biodesix Earnings Call Transcript: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Biodesix Quarterly report: Q3 2025

Nov 3, 2025, 4:30 PM EST - 7 months ago

Biodesix Earnings release: Q3 2025

2025-11-03T21:21:42.000Z - 7 months ago

Biodesix reports Q3 EPS ($1.16), consensus ($1.51)

2025-11-03T21:20:36.000Z - 7 months ago

Biodesix raises FY25 revenue view to $84M-$86M from $80M-$85M, consensus $83.24M

Nov 3, 2025, 4:01 PM EST - 7 months ago

Biodesix Announces Third Quarter 2025 Results and Highlights

Oct 30, 2025, 6:17 AM EDT - 7 months ago

Biodesix to Share its R&D Roadmap during its Corporate Day Presentation at AMP Annual Meeting

Oct 22, 2025, 6:17 AM EDT - 8 months ago

Biodesix Announces Expanded Bio-Rad Laboratories Partnership Agreement to Develop Droplet Digital™ PCR High Complexity Assays

Oct 20, 2025, 6:00 AM EDT - 8 months ago

Biodesix to Report Third Quarter 2025 Financial Results on November 3, 2025

Oct 15, 2025, 6:09 AM EDT - 8 months ago

Biodesix Announces Presentations and Events at the CHEST 2025 Annual Meeting

Oct 6, 2025, 10:13 AM EDT - 8 months ago

Biodesix Unveils October Lung Health Events in Colorado with the Association of Pulmonary Advanced Practice Providers (APAPP), American Lung Association in Colorado, and GO2 for Lung Cancer Centers of Excellence Summit

Sep 11, 2025, 8:00 AM EDT - 9 months ago

Biodesix Announces One-for-Twenty Reverse Stock Split

Sep 5, 2025, 6:00 AM EDT - 9 months ago

Biodesix to Participate in Lake Street Capital Markets' 9th Annual Best Ideas Growth (BIG9) Conference

Aug 19, 2025, 9:47 AM EDT - 10 months ago

Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics

Aug 12, 2025, 4:30 PM EDT - 10 months ago

Biodesix Transcript: Canaccord Genuity’s 45th Annual Growth Conference

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Biodesix Earnings Call Transcript: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Biodesix Quarterly report: Q2 2025

Aug 7, 2025, 4:30 PM EDT - 10 months ago

Biodesix Earnings release: Q2 2025

Aug 7, 2025, 4:06 PM EDT - 10 months ago

Biodesix Announces Second Quarter 2025 Results and Highlights

Aug 6, 2025, 6:00 PM EDT - 10 months ago

Biodesix Slides: Corporate Presentation

Aug 5, 2025, 6:00 AM EDT - 10 months ago

Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 6:00 AM EDT - 11 months ago

Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025

Jun 10, 2025, 6:17 AM EDT - 1 year ago

Biodesix Partners with Association of Pulmonary Advanced Practice Providers (APAPP) to Deliver Nation's First Medical Education for APPs on Biomarkers in Lung Nodule and Lung Cancer Programs

Jun 4, 2025, 10:20 AM EDT - 1 year ago

Biodesix Transcript: 45th Annual William Blair Growth Stock Conference

Jun 4, 2025, 7:00 AM EDT - 1 year ago

Biodesix Slides: Corporate Presentation

May 22, 2025, 5:03 PM EDT - 1 year ago

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

May 15, 2025, 6:00 AM EDT - 1 year ago

Biodesix Announces New Clinical and Economic Data for its Nodify Lung® Tests at ISPOR and ATS

May 14, 2025, 4:01 PM EDT - 1 year ago

Denver Post Names Biodesix a Winner of Top Workplaces 2025 Award

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Quarterly report: Q1 2025

May 13, 2025, 4:30 PM EDT - 1 year ago

Biodesix Earnings release: Q1 2025

May 13, 2025, 4:01 PM EDT - 1 year ago

Biodesix Announces First Quarter 2025 Results and Highlights

Apr 29, 2025, 6:00 AM EDT - 1 year ago

Biodesix to Report First Quarter 2025 Financial Results on May 13, 2025

Apr 28, 2025, 8:00 AM EDT - 1 year ago

Biodesix Proxy statement: Proxy Filing

Apr 23, 2025, 6:00 AM EDT - 1 year ago

Biodesix partner, Friends of Cancer Research, publishes data in Clinical Cancer Research, demonstrating strong association between ctDNA changes and treatment outcomes for patients with solid tumor types

Apr 17, 2025, 8:00 AM EDT - 1 year ago

Biodesix Proxy statement: Proxy Filing

Mar 5, 2025, 1:50 PM EST - 1 year ago

Biodesix Transcript: TD Cowen 45th Annual Healthcare Conference

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Earnings Call Transcript: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Annual report: Q4 2024

Mar 3, 2025, 4:30 PM EST - 1 year ago

Biodesix Earnings release: Q4 2024

Mar 3, 2025, 4:01 PM EST - 1 year ago

Biodesix Announces Fourth Quarter and Fiscal Year 2024 Results

Feb 26, 2025, 6:00 AM EST - 1 year ago

Biodesix to Present at TD Cowen 45th Annual Health Care Conference

Feb 18, 2025, 6:00 AM EST - 1 year ago

Biodesix to Report Fourth Quarter and Full Year 2024 Financial Results on March 3, 2025

Jan 10, 2025, 6:00 AM EST - 1 year ago

Biodesix Announces Preliminary Fourth Quarter and Full-Year 2024 Results (Unaudited)

Jan 7, 2025, 6:00 AM EST - 1 year ago

Biodesix Announces Publication of a New Nodify CDT® Clinical Validation Study

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Quarterly report: Q3 2024

Nov 1, 2024, 8:30 AM EDT - 1 year ago

Biodesix Earnings release: Q3 2024

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Biodesix Registration statement: Registration Filing

Nov 1, 2024, 8:00 AM EDT - 1 year ago

Biodesix Registration statement: Registration Filing

Nov 1, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces Third Quarter 2024 Results and Highlights

Oct 29, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Participate in Three Investor Conferences in November

Oct 18, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024

Oct 7, 2024, 6:00 AM EDT - 1 year ago

Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study

Sep 5, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Present at Two Investor Conferences in September

Aug 14, 2024, 1:00 PM EDT - 1 year ago

Biodesix Transcript: Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Biodesix Earnings Call Transcript: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Biodesix Quarterly report: Q2 2024

Aug 7, 2024, 4:30 PM EDT - 1 year ago

Biodesix Earnings release: Q2 2024

Aug 7, 2024, 4:01 PM EDT - 1 year ago

Biodesix Announces Second Quarter 2024 Results and Highlights

Aug 6, 2024, 6:00 AM EDT - 1 year ago

Biodesix to Present at Canaccord Genuity's 44th Annual Growth Conference

Jul 24, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Report Second Quarter 2024 Financial Results on August 7, 2024

Jun 18, 2024, 8:13 AM EDT - 2 years ago

Biodesix Named to Inc. Magazine's 2024 “Best Workplaces”

Jun 6, 2024, 8:30 AM EDT - 2 years ago

Biodesix Transcript: Jefferies Global Healthcare Conference

Jun 4, 2024, 11:40 AM EDT - 2 years ago

Biodesix Transcript: The 44th Annual William Blair Growth Stock Conference

May 28, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Participate in Two Investor Conferences in June

May 24, 2024, 8:00 AM EDT - 2 years ago

Biodesix Registration statement: Registration Filing

May 21, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Present New Data on the Nodify XL2® Test at ATS 2024 Annual Meeting

May 14, 2024, 1:35 PM EDT - 2 years ago

Biodesix Transcript: 2024 RBC Capital Markets Global Healthcare Conference

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings Call Transcript: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Quarterly report: Q1 2024

May 8, 2024, 4:30 PM EDT - 2 years ago

Biodesix Earnings release: Q1 2024

May 8, 2024, 4:01 PM EDT - 2 years ago

Biodesix Announces First Quarter 2024 Results Driven by Growth in Lung Diagnostic Testing for Lung Nodule Management

May 7, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Participate in the 2024 RBCCM Global Healthcare Conference

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Biodesix Proxy statement: Proxy Filing

Apr 26, 2024, 8:00 AM EDT - 2 years ago

Biodesix Proxy statement: Proxy Filing

Apr 24, 2024, 6:00 AM EDT - 2 years ago

Biodesix to Report First Quarter 2024 Financial Results on May 8, 2024

Apr 23, 2024, 8:00 AM EDT - 2 years ago

Biodesix Registration statement: Registration Filing

Apr 16, 2024, 8:00 AM EDT - 2 years ago

Biodesix Proxy statement: Proxy Filing

Apr 9, 2024, 5:00 PM EDT - 2 years ago

Biodesix to Present New Data on Liquid Biopsy Technologies at AACR 2024 Annual Meeting

supplySHOCK Jun. 4 at 10:09 AM

$NSYS $AKAN $BDSX $SMX figure

0 · Reply

supplySHOCK Jun. 3 at 9:08 PM

$BDSX $SNSE $AIOS $AKTX name

0 · Reply

G101SPM May. 22 at 12:59 PM

0 · Reply

focafoca99 May. 20 at 8:34 PM

$BDSX elected two new Class III directors at its 2026 annual meeting.

0 · Reply

AdrianCartier May. 5 at 6:51 PM

$BDSX finally some green

0 · Reply

Johndoe456 May. 5 at 2:57 PM

$BDSX

0 · Reply

topstockalerts May. 5 at 11:01 AM

Pre Market Top Gainers PT2 $VEEE $EVER $BDSX $PINS $GURE

0 · Reply

captain5500 May. 5 at 8:14 AM

$BDSX delivered on earnings 💥💥

0 · Reply

topstockalerts May. 5 at 1:58 AM

After Hours Top Gainers PT2 $GSUN $CWD $BDSX $EVER $PINS

0 · Reply

StocktwitsEarnings May. 4 at 8:09 PM

0 · Reply

BillionerOfKing May. 4 at 10:22 AM

$BDSX Current Stock Price: $11.13

0 · Reply

stockToph Apr. 30 at 4:39 PM

$BDSX we’re up- keep it up

0 · Reply

stockToph Apr. 30 at 4:11 PM

$BDSX keep buying we’re going up

0 · Reply

stockToph Apr. 30 at 3:50 PM

$BDSX buy buy buy

0 · Reply

Vandenberg23 Apr. 23 at 9:00 PM

$BDSX Wow, never thought I'd see this. Biodesix has a lower market cap than a down-trodden pharma company called Cardiff Oncology. Essentially Biodesix is trading like a penny stock.

0 · Reply

Johndoe456 Apr. 23 at 5:22 PM

$BDSX

0 · Reply

focafoca99 Apr. 9 at 9:08 PM

$BDSX announced a workplace culture award, so this one is more about employer branding than business fundamentals.

0 · Reply

ksoth12 Mar. 20 at 7:44 PM

$BDSX wow this has gotten silly. Such a hard drop on very low volume. Seems like manipulation. Everything is going right for this company and has obviously turned a corner. Seems silly to sell into this drop.

0 · Reply

Zezo88 Mar. 20 at 7:04 PM

$BDSX The average comprises four short-term price targets ranging from a low of $20.00 to a high of $40.00....

0 · Reply

Zezo88 Mar. 20 at 2:36 PM

$BDSX

0 · Reply

Stock_Catcher Mar. 20 at 12:06 PM

$BDSX Biodesix Announces the Largest Lung Nodule Biomarker Clinical Validation Study Ever Published Supporting Earlier Lung Cancer Diagnosis

0 · Reply

Word0025 Mar. 12 at 2:06 PM

$BDSX reached 52wh

0 · Reply

Market Cap	166.73M
Revenue (ttm)	88.50M
Net Income (ttm)	-35.27M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-39.85%
Debt to Equity Ratio	5.09

Volume	41,700
Avg Vol	64,458
Day's Range	N/A - N/A
Shares Out	10.36M
Stochastic %K	76%
Beta	0.59
Analysts	Strong Sell
Price Target	$30.50